English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/121873
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


A nuclear budding mechanism in transiently arrested cells generates drug-sensitive and drug-resistant cells

AuthorsMansilla, Sylvia CSIC ORCID; Bataller, Marc CSIC; Portugal, José CSIC ORCID
Issue Date5-Apr-2009
CitationBiochemical Pharmacology 78(2): 123-132 (2009)
AbstractHCT116 (p53+/+) human colon carcinoma cells treated with nanomolar concentrations of doxorubicin underwent transient senescence, synthesized DNA, showed endopolyploidization, increased their size and became multinucleated without a significant increase in mitosis. Nuclei underwent a budding process that involved the release of buds outside the nuclear membrane, and some of the buds seemed to escape from the polyploid cells. A clonogenic assay showed that some cells proliferated following the initial treatment. In general, cells ensuing after budding were not resistant to a variety of drugs, although some of them turned out to be resistant, indicating a potential selective advantage. Nuclear budding was accompanied by changes in protein levels in the giant cells, including inhibition of p53 and enhanced expression of p21WAF1 and the meiosis-related Mos. The buds might be a mechanism for the segregation and elimination of redundant DNA, or for generating viable aneuploid cells with a potentially extended life span. © 2009 Elsevier Inc. All rights reserved.
Publisher version (URL)http://dx.doi.org/10.1016/j.bcp.2009.03.027
Identifiersdoi: 10.1016/j.bcp.2009.03.027
issn: 0006-2952
Appears in Collections:(IBMB) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.